At every MedTech funding stage, investors want to see specific MDR deliverables that de-risk the next milestone. Pre-seed needs a credible intended purpose and classification. Seed needs a signed regulatory strategy and a live QMS. Series A needs a Clinical Evaluation Plan, Notified Body engagement, and a realistic certification timeline. Miss any of these and valuation suffers — or the round does not close.

By Tibor Zechmeister and Felix Lenhard.

TL;DR

  • Each funding round in MedTech is underwritten against specific regulatory milestones, not just product milestones.
  • Pre-seed expects a clear intended purpose per MDR Article 2(12), a defensible classification under Annex VIII, and a named Person Responsible for Regulatory Compliance plan under Article 15.
  • Seed expects a signed regulatory strategy, a live QMS compatible with EN ISO 13485:2016+A11:2021, risk management under EN ISO 14971:2019+A11:2021, and a draft Clinical Evaluation Plan.
  • Series A expects Notified Body contact under MDR Article 52, a complete Clinical Evaluation Plan under Article 61 and Annex XIV, significant technical documentation progress, and a credible 12 to 24 month certification timeline.
  • Common investor red flags: no PRRC, vague intended purpose, no classification rationale, no CER plan, and budget lines that do not trace to MDR obligations.
  • Due diligence in 2027 is tighter than in 2024. Investors burned by MDR timeline surprises now demand evidence, not confidence.

Why investors care about regulatory milestones

In software, investors fund features and users. In MedTech, investors fund regulatory milestones because the milestones are what unlock the next tranche of value. A pre-clinical Class IIa device with no regulatory plan is nearly worthless. The same device with a signed Clinical Evaluation Plan and an engaged Notified Body is worth an order of magnitude more — not because the product changed, but because the path to market became concrete.

This is why MedTech term sheets in 2027 read like regulatory project plans. Investors have been burned. The 2024 to 2026 transition period taught a generation of European VCs that MDR timelines are real, that Notified Body queues are real, that clinical evidence requirements under MDR Article 61 are meaningfully higher than under the old Directives, and that a founder who waves away regulatory work is a founder about to miss every milestone in the investment memo.

The funding checklist that follows maps each round to the specific MDR deliverables a 2027 investor will expect to see in their data room. It is not exhaustive — your specific device class, clinical setting, and business model will add items — but it is the floor.

What MDR actually says about your funding stages

The MDR does not mention venture capital. But its structure dictates the gates that fundable milestones have to cross.

MDR Article 5 establishes that a device may only be placed on the EU market if it complies with the Regulation. Article 10 lists the general manufacturer obligations, which include having a QMS, a PRRC, technical documentation, a clinical evaluation, and a post-market surveillance system. Article 15 defines the PRRC role and permits contractual arrangements for micro and small enterprises. Article 52 sets out the conformity assessment procedures, which for most classes above Class I require Notified Body involvement. Article 61 and Annex XIV define the clinical evaluation requirements. Annex VIII contains the classification rules that determine which conformity assessment route applies.

Each of these articles becomes a due diligence checkpoint at a different round. Pre-seed investors want to know that classification and intended purpose are defensible. Seed investors want evidence that the QMS and risk management engines are running. Series A investors want to see that Article 52 and Article 61 deliverables are under way and tied to a timeline.

A worked example: Class IIa SaMD startup, three rounds

Consider a Class IIa SaMD startup targeting clinical decision support for a specific radiology workflow. Here is what each round realistically looks like from the regulatory side.

Pre-seed, 600,000 euros, founders plus angels. At this stage the investor is underwriting the founder and the opportunity. The regulatory ask is: can you explain, in writing, what your device does, who uses it, and what its intended purpose is under MDR Article 2(12)? Can you point to the classification rule under Annex VIII that applies — most likely Rule 11 for software — and justify your preliminary class? Do you have a plan for the PRRC obligation under Article 15, even if it is "we will contract a fractional PRRC at seed"? A pre-seed investor who cannot get clear answers to those three questions will either pass or mark the round down.

Seed, 2.5 million euros, institutional. Now the investor is underwriting the path. The regulatory ask escalates. You need a written regulatory strategy signed by a named regulatory lead. You need a QMS that is actually running, compatible with EN ISO 13485:2016+A11:2021, even if it is lean and document-based. You need a risk management file under EN ISO 14971:2019+A11:2021 with at least initial hazard analysis and risk controls traced to design inputs. You need a draft Clinical Evaluation Plan under Annex XIV Part A. You need a PRRC arrangement that is real, not aspirational. You need a credible MDR budget that ties each line to an Article 10 obligation.

Series A, 8 to 15 million euros, lead investor plus syndicate. The investor is underwriting certification itself. At this stage due diligence will include an external regulatory review. You need Notified Body contact initiated under Article 52, ideally with a signed application or at minimum a confirmed queue position. You need a complete Clinical Evaluation Plan and a clinical data strategy that explains whether equivalence is claimed and, if so, on what grounds. You need most of the technical documentation drafted. You need a PMS plan per Annex III. You need a realistic 12 to 24 month certification timeline with gates, dependencies, and risk buffers. You need a valuation story that ties the Series A milestones to a specific CE mark date.

Miss these, and the round either does not close or closes at a valuation that destroys founder equity.

The Subtract to Ship funding checklist

Use this as a data-room checklist before you pitch.

Pre-seed regulatory checklist

  • Written intended purpose per MDR Article 2(12), one paragraph, unambiguous
  • Preliminary classification per MDR Annex VIII with the specific rule cited
  • User group, use environment, and clinical workflow described
  • Preliminary competitor and predicate analysis
  • PRRC plan under Article 15 (even if "contract at seed")
  • Budget showing first 18 months of regulatory spend
  • Founder regulatory literacy evidence: the founder can explain MDR Article 10 without a cheat sheet

Seed regulatory checklist

  • Signed regulatory strategy document covering classification, conformity assessment route, clinical evidence approach, and timeline
  • Active QMS compatible with EN ISO 13485:2016+A11:2021
  • Risk management file under EN ISO 14971:2019+A11:2021 with initial hazard analysis
  • Draft Clinical Evaluation Plan per Annex XIV Part A
  • Draft technical documentation structure per Annexes II and III
  • PRRC arrangement in place under Article 15
  • Named regulatory lead (fractional or in-house)
  • Notified Body long-list with preferred choices identified
  • 24-month burn forecast with each line traced to an MDR obligation

Series A regulatory checklist

  • Notified Body contact initiated, queue position confirmed, contract or quote on file
  • Complete Clinical Evaluation Plan per Article 61 and Annex XIV
  • Clinical data strategy: equivalence, literature, prospective data, or a combination
  • Draft Clinical Evaluation Report or, at minimum, complete literature search
  • Technical documentation substantially drafted and under version control
  • Post-market surveillance plan per Annex III
  • Vigilance process defined per Articles 87 to 92
  • Signed PRRC contract or job description per Article 15
  • 12 to 24 month certification timeline with named gates, owners, and risk buffers
  • External regulatory review report (many lead investors commission this themselves)
  • Board-level regulatory KPIs and reporting cadence

Investor red flags to avoid

From sitting on both sides of the table, these are the red flags that kill MedTech rounds in 2027:

No PRRC. The first thing experienced MedTech investors check. No PRRC plan means the founder has not read MDR Article 15, which means they have not read MDR Article 10, which means they have probably not read the MDR at all.

Vague intended purpose. "We help clinicians make better decisions" is not an intended purpose under MDR Article 2(12). It has to say, specifically, what the device does, for whom, in what setting, and what clinical claim it makes.

No classification rationale. Saying "we think we are Class IIa" without citing the Annex VIII rule is a sign the founder has outsourced thinking to hope.

Missing CER plan. Clinical evidence is the line item most commonly underestimated. No CEP at Series A is a hard fail.

Budget lines that do not trace to MDR obligations. Padding is visible. Gaps are visible. A regulatory budget that does not mention Notified Body fees, clinical evaluation, risk management, PMS, and QMS certification is not a budget — it is a wish.

Founder who cannot answer Notified Body timeline questions. If you cannot explain the difference between Stage 1 and Stage 2, or what Annex IX, X, and XI mean for your device, you are not ready for Series A.

Over-reliance on equivalence. Post-MDR, equivalence is harder to claim than under the MDD. Investors know this. A CER plan that assumes equivalence without a rigorous three-pillar analysis is a pitch that will not survive regulatory diligence.

Reality Check

  1. Can you state your intended purpose in one paragraph without editing?
  2. Can you cite the Annex VIII rule that drives your classification?
  3. Do you have a named PRRC or a signed contract for one?
  4. Does your budget show every MDR obligation from Article 10 as a line item?
  5. Have you contacted at least three Notified Bodies and understood current queue times?
  6. Can you explain your clinical evidence strategy to an investor in five minutes?
  7. Is your QMS actually running, or does it exist only in a Google Doc titled "QMS plan"?
  8. Would your Series A deck survive an external regulatory diligence review commissioned by the lead investor?

Frequently Asked Questions

How much of a MedTech Series A should be earmarked for regulatory work? For a Class IIa SaMD, typically 25 to 40 percent of the round funds regulatory, clinical, and QMS activities through CE mark. Hardware devices often run higher because of testing and verification costs.

When should I first contact a Notified Body? As soon as you can describe your device, its intended purpose, and its preliminary classification clearly — typically late seed or early Series A. Queue positions matter and securing one early is a legitimate fundraising narrative.

Can I raise Series A without a signed Notified Body contract? Yes, but you need confirmed engagement and queue visibility. Many lead investors will release tranches against Notified Body milestones.

Do investors accept a fractional PRRC? Yes, provided it complies with MDR Article 15(1) conditions for micro and small enterprises and the contract is genuine.

What if my classification changes between rounds? Disclose it immediately. An up-classification from IIa to IIb changes the conformity assessment route and the budget. Hiding it until Series A diligence will kill the round.

How do I defend my CE mark timeline to investors? Show the gating chart: QMS readiness, technical documentation completeness, clinical evaluation status, Notified Body queue position, Stage 1 and Stage 2 audit dates, and post-audit non-conformity buffer. Timelines without buffers are not credible.

Sources

  1. Regulation (EU) 2017/745 on medical devices, consolidated text. Articles 2(12), 5, 10, 15, 52, 61, 83-86, 87-92; Annexes II, III, VIII, IX, X, XI, XIV.
  2. EN ISO 13485:2016+A11:2021 — Medical devices — Quality management systems.
  3. EN ISO 14971:2019+A11:2021 — Medical devices — Application of risk management to medical devices.